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Hepatocellular carcinoma (HCC) is the most preva-
lent subtype of liver cancer, and it is characterized
by a high rate of recurrence and heterogeneity. Liver
cancer stem cells (CSCs) may well contribute to both
of these pathological properties, but the mecha-
nisms underlying their self-renewal and maintenance
are poorly understood. Here, using transcriptome
microarray analysis, we identified a long noncoding
RNA (lncRNA) termed lncTCF7 that is highly ex-
pressed in HCC tumors and liver CSCs. LncTCF7
is required for liver CSC self-renewal and tumor prop-
agation. Mechanistically, lncTCF7 recruits the SWI/
SNF complex to the promoter of TCF7 to regulate
its expression, leading to activation of Wnt signaling.
Our data suggest that lncTCF7-mediated Wnt sig-
naling primes liver CSC self-renewal and tumor prop-
agation. In sum, therefore, we have identified an
lncRNA-based Wnt signaling regulatory circuit that
promotes tumorigenic activity in liver cancer stem
cells, highlighting the role that lncRNAs can play in
tumor growth and propagation.
INTRODUCTION
Liver cancer is the fifthmost commonly diagnosedcancer and the
second most frequent cause of cancer death in men worldwide
(Jemal et al., 2011). Hepatocellular carcinoma (HCC) represents
the major histological subtype, accounting for 70%–85% of
cases of primary liver cancer. Unfortunately, the 5-year survival
rate of HCC subjects remains poor, and more than 750,000
HCC subjects die each year. Although previous studies identified
many aberrantly expressed protein-coding genes in HCC, novel
molecular markers that can help in early diagnosis and risk
assessment are still urgently needed (Ji et al., 2009; Yamashita
andWang, 2013). New therapeutic approachesare likely to derive
from an improved understanding of the molecular basis of HCC.The high rate of recurrence and heterogeneity are the two
major features of HCC (Visvader, 2011). Recent studies have
suggested that heterogeneity is a result of the hierarchical orga-
nization of tumor cells by a subset of cells with stem/progenitor
cell features known as cancer stem cells (CSCs) (Easwaran et al.,
2014). These CSCswithin tumor bulk display the capacity to self-
renew, differentiate, and give rise to a new tumor (Visvader and
Lindeman, 2012), accounting for a hierarchical organization of
heterogeneous cancer cells and a high rate of cancerous recur-
rence. Liver CSCs can be enriched with several defined surface
markers, including epithelial cell adhesion molecule (EpCAM),
CD133, CD13, CD90, CD44, CD24, and calcium channel a2d1
subunit, among others (Haraguchi et al., 2010; Lee et al., 2011;
Ma et al., 2007; Zhao et al., 2013). However, how liver CSCs sus-
tain their self-renewal remains largely unknown.
Long noncoding RNAs (lncRNAs) are defined as transcripts
longer than 200 nucleotides (nt) that are 50 capped and 30 polya-
denylated, yet this class of transcripts has limited coding poten-
tial. LncRNAs function in a wide range of biological processes
and can regulate gene expression in cis or in trans by diverse
mechanisms (Batista and Chang, 2013; Cech and Steitz,
2014; Ulitsky and Bartel, 2013). LncRNA-mediated biology has
been implicated in many cellular processes (Ulitsky and Bartel,
2013). In cancer, lncRNAs have been reported to act as a prom-
inent layer of transcriptional regulation, often by collaborating
with chromatin remodeling complexes (Gupta et al., 2010; Pre-
nsner et al., 2013; Yang et al., 2013; Yuan et al., 2014). The
SWI/SNF complex is an evolutionally conserved multisubunit
complex that mobilizes nucleosomes and remodels chromatin
using the energy of ATP hydrolysis (Helming et al., 2014; Wilson
and Roberts, 2011). The SWI/SNF complex associates with tran-
scription factors, coactivators, or coexpressors to regulate gene
expression (Tolstorukov et al., 2013; You et al., 2013). Inactivat-
ing mutations in several SWI/SNF subunits have been identified
in various human cancers (Jones et al., 2010; Kadoch et al.,
2013; Li et al., 2011), suggesting that mutations of some individ-
ual subunits promote tumorigenesis. Additionally, the SWI/SNF
complex has been implicated in being involved in controlling
mammalian stem cell self-renewal and differentiation (Eroglu
et al., 2014; Yu et al., 2013; Zeng et al., 2013). However, how
the SWI/SNF complex functions in CSCs remains elusive. InCell Stem Cell 16, 413–425, April 2, 2015 ª2015 Elsevier Inc. 413
this study, we found that lncTCF7 is required for the self-renewal
maintenance of liver CSCs. LncTCF7 recruits the SWI/SNF com-
plex to trigger TCF7 expression, leading to activation of Wnt
signaling for priming liver CSC self-renewal.
RESULTS
LncTCF7 Is Highly Expressed in Liver CSCs
Although CD13 (Haraguchi et al., 2010) and CD133 (Ma et al.,
2007) have been widely used as liver CSC surface markers,
CD133 or CD13 alone could enrich more cell populations in
HCC cell lines or HCC primary samples (Figures S1A and S1B).
Haraguchi et al. (2010) demonstrated that the CD13+CD133+
cell fraction exhibited slow growth compared with their counter-
part CD13CD133 cells. Moreover, the CD13+CD133+ cell frac-
tion was highly resistant to chemical drug treatments compared
with their CD13CD133 subset. Notably, we observed that the
CD13+CD133+ cell subsets were successfully enriched in seven
cell lines out of nine HCC cell lines we tested and in over 90% of
30 HCC primary samples we examined (Figure S1B). Thus, we
combined CD13 and CD133 to enrich the CD13+CD133+ cell
fraction and thereby identify them as hepatic CSCs in this study.
We then sorted CD13+CD133+ cells, presumptively liver
CSCs, from Hep3B, Huh7, and PLC/PRF/5 HCC cell lines.
Actually, the CD13+CD133+ subset derived from Hep3B cells
significantly enhanced oncosphere formation compared to
CD13CD133 cells (10.3% ± 1.3% versus 2.6% ± 0.3%; p =
0.003) (Figure S1C). In addition, the tumor sphere formation
frequencies of CD13+CD133+ and CD13+CD133 subsets of
Hep3B cells were 10.3% ± 1.3% versus 6.1% ± 1.1% (p =
0.0253); CD13+CD133+ versus CD13CD133+ fractions of
Hep3B cells were 10.3% ± 1.3% to 5.2% ± 1.3% (p = 0.0226)
(Figure S1C). Similar observations were obtained using Huh7
and PLC/PRF/5 cells (Figure S1C). Consistently, the tumor-initi-
ating ability of the CD13+CD133+ subset derived from Hep3B
cells was significantly higher than that of CD13+ or CD133+ cells
alone (Figures S1D and S1E). Similar results were achieved with
Huh7 cells. We concluded that the tumorigenic capacity of
CD13+CD133+ cells was much higher than that of CD13+ or
CD133+ cells alone. Of note, there was no significant difference
in the proliferative capacity between CD13+CD133+ cells and
CD13CD133 cells through cell-cycle analysis (Figure S1F).
To identify lncRNAs involved in liver CSCs, we conducted tran-
scriptome microarray analysis of CD13+CD133+ cells (hereafter
called liver CSCs) and CD13CD133 cells (hereafter referred
to as non-CSCs) sorted from the three above mentioned HCC
cell lines. 286 noncoding RNA transcripts were aberrantly ex-
pressed in liver CSCs compared with non-CSCs (Figure 1A),
with some of those differential lncRNAs validated in liver CSCs
when we detected ten randomly selected lncRNAs (Figure S1G).
Since lncRNAs can act in cis to regulate expression of neigh-
boring genes or in transbydiversemechanisms (Rinn andChang,
2012), we concentrated on intergenic lncRNAs, whichwere high-
ly expressed in liver CSCs and located in the nearby stem tran-
scription factors and coding genes related to stem signaling
pathways. Among these highly expressed intergenic lncRNAs,
we focused on an uncharacterized lncRNA, termed lncTCF7
(gene symbol TCONS_00009511-XLOC_004555). LncTCF7 is
one of the most highly expressed lncRNAs in liver CSCs (Fig-414 Cell Stem Cell 16, 413–425, April 2, 2015 ª2015 Elsevier Inc.ure1AandFigureS1G), residingonchromosome5 inhumansbe-
tween the heat shock 70 kDa protein 4 (HSPA4) and T cell factor 7
(TCF7) genes (Figure 1B). LncTCF7 was composed of three
exons and spanned nearly 3.6 kilobases (kb), identifying it as a
modestly conserved locus. We further confirmed that lncTCF7
washighly expressed in liverCSCs (Figure 1C), aswell as in onco-
sphere cells derived from HCC cell lines and HCC primary sam-
ples (Figures 1D and 1E).We next examined a cohort of 37 paired
HCC tumor andperi-tumor tissues, alongwith 14 hepatitis B virus
(HBV)-infected liver cirrhotic tissues and 8 normal liver tissues
(Table S1).Weobserved that lncTCF7was significantly highly ex-
pressed in HCC tumors (Figure 1F and Figure S1H) and HCC cell
lines (Figure S1I), whereas it was almost undetectable in liver
cirrhosis samples and healthy liver tissues (Figure 1F and Fig-
ure S1H). In addition, lncTCF7 was not detectable in some other
normal primary tissues we examined (Figure S1J), suggesting a
more restricted fashion of lncTCF7 expression.
We further examined the transcripts of lncTCF7 in liver CSCs
by northern blot. Only one transcript variant of lncTCF7 was in
liver CSCs, with a length between 500 to 1,000 bases (Figure 1G).
However, lncTCF7 expression was much lower in non-CSCs. A
total length of 683 nt of lncTCF7 transcript was determined by
a rapid amplification of cDNA ends (RACE) assay (Figure S1K),
which displayed no coding potentiality (Figures S1L and S1M).
Furthermore, lncTCF7 was localized in the nuclei of HCC tumor
cells through RNA fluorescence in situ hybridization (RNA-
FISH) and cellular fractionation assays (Figures 1H and 1I).
LncTCF7 was highly expressed in oncosphere cells, but it was
poorly expressed in non-sphere tumor cells. These data indicate
that lncTCF7, as an lncRNA, was highly expressed in HCC tumor
tissues and liver CSCs.
LncTCF7 Is Required for Self-Renewal Maintenance of
Liver CSCs
To determine the role of lncTCF7 in liver CSC self-renewal, we
silenced lncTCF7 against either exon 1 or 3 in liver CSCs using
lentivirus-mediated short hairpins RNAs (shRNAs) (Figure 2A).
shRNA-2 (against exon 3) achieved more effective knockdown
efficiency. Notably, lncTCF7 depletion significantly reduced
the expression of pluripotent transcription factors Sox2, Nanog,
and Oct4 compared with scrambled control (shCtrl) cells
(Figure 2B). By contrast, lncTCF7 knockdown did not affect c-
Myc expression. Actually, c-Myc was highly expressed in both
lncTCF7 silenced and shCtrl liver CSCs, whose expression
was not significantly altered in loss-of-function experiments (Fig-
ure 2B). Additionally, lncTCF7 knockdown remarkably impaired
generation of the fraction of CD13+CD133+ cells (CSCs) (Fig-
ure 2C). Importantly, lncTCF7 depletion dramatically reduced
primary (1st), secondary (2nd), and tertiary (3rd) oncosphere for-
mation of HCC cell lines and HCC primary cells (Figure 2D).
Consistently, lncTCF7 silencing also impaired 2nd and 3rd on-
cosphere formation derived from their primary oncosphere cells.
Similar observations were obtained in lncTCF7 silenced PLC/
PRF/5 cells (data not shown). Consequently, lncTCF7 depletion
in HCC primary tumor cells significantly reduced the expres-
sion of Sox2 and Nanog (Figure 2E). More importantly, we con-
ducted 2nd and 3rd generation xenograft tumor growth for the
CD13+CD133+ cell subsets derived from HCC cell lines and pri-
mary samples. We noticed that CD13+CD133+ cell populations
Figure 1. LncTCF7 Is Highly Expressed in
Liver CSCs
(A) Geometric mean-centered, hierarchical cluster
heat map from microarray data. 286 annotated
noncoding RNAs (p < 0.05) were represented in
liver CSC (CD13+CD133+) compared with non-
CSC (CD13CD133) cells sorted from HCC cell
lines, Hep3B, Huh7, and PLC/PRF/5 (PLC). Black
arrowhead denotes lncTCF7.
(B) Schematic annotation of lncTCF7 genomic lo-
cus on chromosome 5. Blue rectangles represent
exons (upper panel). Sequence conservation was
analyzed by Phylop software (lower panel).
(C) LncTCF7 was detected in liver CSCs and non-
CSCs sorted from HCC cell lines by quantitative
real-time PCR analysis. Relative gene expression
values were normalized to endogenous 18S rRNA
unless noted otherwise in this study. Results are
shown as means ± SD.
(D and E) LncTCF7 was analyzed in oncosphere
and non-oncosphere cells derived from three HCC
cell lines and HCC primary cells. Results are
shown as means ± SD.
(F) LncTCF7 was detected in HCC tumor tissues
paired with adjacent tumor tissues (n = 37), liver
cirrhosis tissues (n = 14), and normal liver tissues
(n = 8). Data were normalized to endogenous 18S
rRNA expression and normal liver tissues were
assigned a value of 1.
(G) A 363 nt probe of lncTCF7 was labeled for
northern blot analysis. RNAs were extracted from
sphere and non-sphere cells derived from HCC
primary specimens. U6 RNA was used as a
loading control.
(H) LncTCF7 intracellular localization was visual-
ized in HCC oncosphere and non-sphere cells by
RNA-FISH assays. Representative images of
lncTCF7 in Huh7 oncosphere (Sphere) and non-
oncosphere cells (Non-sphere) are shown. DAPI,
4’, 6-diamidino-2-phenylindole. Probes, lncTCF7.
Scale bar, 10 mm.
(I) Fractionation of HCC oncosphere cells followed
by quantitative real-time PCR (left panel) and
fractionation controls by immnoblotting (right
panel). U1 RNA served as a positive control for
nuclear gene expression. EEA1, endosome anti-
gen 1; N, Nuclear fraction; C, Cytoplasmic fraction.
Data are shown as means ± SD. *p < 0.05, **p <
0.01, and ***p < 0.001 by two-tailed Student’s t
test. Data are representative of at least three in-
dependent experiments. See also Figure S1 and
Table S1.were still enriched from the 2nd and 3rd generation xenograft tu-
mors (data not shown). The CD13+CD133+ cell populations from
the 2nd and 3rd generation displayed stronger tumor-initiating
capacities (Figure S2A) and oncosphere forming abilities (Fig-
ure S2B), indicating a long-term self-renewal capacity of the
CD13+CD133+ cell population. Moreover, Ki67 signals were
not apparently altered in liver CSCs compared with non-CSCs
(Figure S2C). However, the amount of Sox2 was significantly
increased in liver CSCs, but not in non-CSCs. By contrast,
lncTCF7 overexpression remarkably enhanced Sox2 signals in
liver CSCs, whereas Ki67 was not altered in lncTCF7-overex-
pressing CSCs compared to empty-vector-treated cells (Fig-ureS2D). Similar observationswere obtained in xenograft tumors
(Figure S2E), suggesting lncTCF7-mediated tumorigenicity in
liver cancer is mainly caused by the self-renewal capacity of
CSCs.
We next explored the role of lncTCF7 in tumor-initiating forma-
tion. We performed subcutaneous injection of BALB/c nude
mice with stable knockdown of lncTCF7 and shCtrl cells.
LncTCF7 depletion resulted in a much weaker tumor presence
compared with shCtrl primary tumor cells as assessed by a
limiting dilution xenograft analysis (Figure 2F), suggesting that
lncTCF7 knockdown reduced tumor initiating capacity. More-
over, lncTCF7 depletion significantly suppressed xenograftCell Stem Cell 16, 413–425, April 2, 2015 ª2015 Elsevier Inc. 415
Figure 2. LncTCF7 Is Required for the Self-Renewal Maintenance of Liver CSCs
(A) LncTCF7 was silenced in liver CSCs by two independent shRNAs targeting either exon 1 or 3. LncTCF7-silenced stable cell lines were established. Data are
shown as means ± SD.
(B) Pluripotent transcription factors were analyzed in lncTCF7-depleted cells by quantitative real-time PCR (left penal) and western blot (right panel) analyses.
Quantitative real-time PCR results are shown as means ± SD.
(C) CD13+CD133+ (CSC) subpopulations were detected in lncTCF7-depleted cells by FACS analysis. Results are shown as means ± SD.
(D) LncTCF7 depletion causes a diminished oncosphere-forming capacity in HCC cell lines andHCC primary cells. The right panel represents statistical results as
means ± SD. Scale bar, 100 mm.
(E) Pluripotency transcripts were analyzed in lncTCF7-silenced HCC primary cells by quantitative real-time PCR analysis. Data are shown as
means ± SD.
(F) LncTCF7-silenced or shCtrl HCC primary tumor cells were diluted and subcutaneously implanted into BALB/c nude mice. Tumors were observed over
4 months. n = 12 for each group.
(legend continued on next page)
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Figure 3. LncTCF7 Overexpression Enhances Tumorigenic Capacity of Liver CSCs
(A) LncTCF7-overexpressing HCC primary tumor cells were established. oeVec, overexpression empty vector; oelncTCF7, overexpression of lncTCF7. Data are
shown as means ± SD.
(B) Overexpression of lncTCF7 (oelncTCF7) resulted in elevated expression of pluripotent factors in HCC cells as assessed by quantitative real-time PCR (left) and
western blot (right) analyses. Quantitative real-time PCR data are shown as means ± SD.
(C) LncTCF7 overexpression enhances the capacity of oncosphere formation. Scale bar, 100 mm. oe, overexpression. The right panel represents statistical results
shown as means ± SD.
(D) LncTCF7-overexpressing (oelncTCF7) or empty vector (oeVec) cells derived from HCC primary tumor cells were diluted and subcutaneously implanted into
BALB/c nude mice. Tumors were observed over 4 months. n = 12 for each group.
(E) LncTCF7-overexpressing or vector control (oeVec) treated primary cells were subcutaneously injected into BALB/c nude mice for observation of tumor
growth. Results are shown as means ± SD. n = 10 for each group.
(F) Tumorigenic cell frequency in lncTCF7-overexpressing and empty vector control (oeVec) cells was determined with limiting dilution assays (http://bioinf.wehi.
edu.au/software/elda/). #1, sample #1; #19, sample #19; oe, overexpression; CI, confidence interval.
*p < 0.05, **p < 0.01, and ***p < 0.001 by two-tailed Student’s t test. Data represent at least three independent experiments. See also Figure S3.tumor growth and tumorigenic cell frequency (Figures 2G and
2H). We observed xenograft growth for 4 months and defined
a threshold tumor size for detectability of tumors as 30–
40 mm3. Similar observations were achieved in lncTCF7-
silenced HCC cell lines (Figures S2F–S2H). Overall, lncTCF7
silencing abrogates the tumorigenic capacity of liver CSCs.(G) LncTCF7-silenced or shCtrl HCC primary tumor cells were subcutaneously
shown as means ± SD. n = 12 for each group.
(H) Tumorigenic cell frequency in lncTCF7-depleted and control primary tumo
software/elda/). #1, sample #1; #19, sample #19; CI, confidence interval.
*p < 0.05, **p < 0.01, and ***p < 0.001 by two-tailed Student’s t test. Data represLncTCF7 Overexpression Enhances Tumorigenic
Capacity of Liver CSCs
We next overexpressed lncTCF7 in HCC primary tumor cells
and cell lines and established lncTCF7 stably overexpressing
cell lines (Figure 3A and Figure S3A). LncTCF7 overexpression
dramatically increased expression of pluripotent transcriptioninjected into BALB/c nude mice for observation of tumor growth. Results are
r cells was analyzed with a limiting dilution assay (http://bioinf.wehi.edu.au/
ent at least three independent experiments. See also Figure S2.
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factors (Figure 3B). Notably, lncTCF7 overexpression signifi-
cantly enhanced oncosphere formation and tumor-initiating
capacity (Figures 3C and 3D). Consequently, lncTCF7 overex-
pression dramatically augmented xenograft tumor growth (Fig-
ure 3E) and tumorigenic cell frequency (Figure 3F). We tested
at least six HCC primary samples and achieved similar observa-
tions. Similar results were also observed in lncTCF7-overex-
pressed HCC cell lines such as Hep3B and Huh7 cells (Fig-
ure S3). All together, these data indicate that lncTCF7 plays a
critical role in the self-renewal maintenance of liver CSCs.
LncTCF7 Triggers TCF7 Expression to Activate Wnt
Signaling
To explore the target genes of lncTCF7, we established lncTCF7-
silenced HCC primary CSC cells and conducted transcriptome
microarray analysis. LncTCF7 knockdown resulted in differential
expression of 2,491 genes (Figure S4A), suggesting that lncTCF7
regulates many genes that relate to important signaling pro-
cesses including the Wnt signaling pathway (Figure S4B).
Notably, lncTCF7 knockdown significantly reduced its nearby
protein-coding gene TCF7 and somemajorWnt signaling targets
(Figure 4A). By contrast,HSPA4 and the other neighboring genes
displayed no significant changes. We then validated these ob-
servations in HCC cell lines (Hep3B, Huh7, and PLC) or HCC pri-
mary cells (at least six samples). Consistently, lncTCF7 silencing
remarkably reduced the expression of TCF7 and major Wnt tar-
gets in HCC cell lines and HCC primary cells we examined (Fig-
ures 4B and 4C and Figures S4C and S4D). In contrast, lncTCF7
depletion did not alter the expression of HSPA4 and the other
neighboring genes (Figures S4C and S4E). In addition, lncTCF7
overexpression in HCC cell lines or HCC primary cells remark-
ably enhanced the expression of TCF7 and major Wnt targets
(Figure S4F). These data suggest that lncTCF7 activates the
Wnt signaling pathway in HCC.
We further tested the expression levels of lncTCF7 and TCF7
in HCC subjects by quantitative real-time PCR. We noticed
that lncTCF7 expression was positively correlated with the
expression of TCF7 (Pearson correlation coefficient r = 0.693,
p < 0.001) (Figure 4D). To determine whether lncTCF7 functionsFigure 4. LncTCF7 Triggers TCF7 Expression to Activate Wnt Signalin
(A) Mean-centered, hierarchical clustering of genes altered in lncTCF7-silenced
(B) Differential genes were validated in lncTCF7-silenced HCC cell lines and HC
silenced cell lines (Hep3B, Huh7, and PLC) and six HCC primary specimens we e
means ± SD.
(C) TCF7 and CCND2 were analyzed by immunoblotting.
(D) Expression levels of lncTCF7 and TCF7 were detected in 30 HCC sample
expression and shown as DCT (threshold cycle).
(E) TCF7 was overexpressed in lncTCF7-silenced Huh7 cells. oe, overexpression
(F) TCF7 overexpression rescues sphere formation ability reduced by lncTCF7 de
100 mm. Percentages of sphere-forming cells were calculated as means ± SD (ri
(G) TCF7 was detected in HCC tumor and peri-tumor tissues (n = 30) by weste
Quantitative real-time PCR data were normalized to 18S rRNA expression and p
(H) TCF7 was visualized in Huh7 oncosphere and non-sphere cells by immunoflu
(I) TCF7 was detected in HCC samples by immunohistochemistry staining. Scale
(J) TCF7 was analyzed in live (n = 48) and dead (n = 32) HCC subjects in accorda
(K) Sox2 was detected in TCF7-depleted or shCtrl HCC cells.
(L) TCF7 depletion reduces the rate of oncosphere formation in cells derived from
(M and N) TCF7 depletion reduces tumor-initiating capacity (M) and tumorigenic c
au/software/elda/). CI, confidence interval.
*p < 0.05 and **p < 0.01 by two-tailed Student’s t test. Data are representative oupstream of TCF7 in the regulation of liver CSC self-renewal, we
rescued TCF7 expression in lncTCF7-silenced HCC cells (Fig-
ure 4E). Interestingly, TCF7 restoration rescued the oncosphere
formation ability reduced by lncTCF7 depletion (Figure 4F).
Additionally, TCF7 restoration also rescued lncTCF7-depletion-
reduced tumor-initiating capacity and xenograft tumor growth
(data not shown). LncTCF7 silencing dramatically downregu-
lated expression of some major Wnt molecules, including
Wnt7a, Wnt4, and Wnt2b (Figures 4A and 4B). Among these
three Wnt molecules, lncTCF7 depletion reduced expression of
Wnt7a the most. To further validate whether Wnt7a is a down-
stream effector of lncTCF7, we incubated lncTCF7-silenced
HCC primary CSCs with recombinant Wnt7a for a sphere
formation assay. We found that Wnt7a rescued the oncosphere
formation ability reduced by lncTCF7 depletion (Figure S4G).
Additionally, Wnt7a also restored the expression levels of
TCF7, Sox2, and Nanog in lncTCF7-depleted HCC primary
CSCs (Figure S4H). DKK1 (Dickkopf-related protein 1) was re-
ported to be an extracellular inhibitor of Wnt signaling (Cui
et al., 2013). The presence of DKK1was able to abolish the onco-
sphere formation ability enabled by lncTCF7 overexpression
(Figure S4I). Consistently, DKK1 treatment also impeded the
expression levels of TCF7, Sox2, and Nanog in lncTCF7-overex-
pressing HCC primary CSC cells (Figure S4J). These data
suggest that lncTCF7 sustains the self-renewal of liver CSCs up-
stream of TCF7.
To further explore the clinical implications of TCF7 in HCC, we
analyzed the expression of TCF7 in HCC tumor and peri-tumor
tissues. We observed that TCF7 was highly expressed in HCC
tumors (Figure 4G). Additionally, TCF7 was mainly localized in
the nuclei of HCC oncosphere cells, whereas it was almost unde-
tectable in non-sphere cells (Figure 4H). High expression of TCF7
in HCC samples was further confirmed by immunohistochem-
istry staining (Figure 4I). Importantly, high expression of TCF7
predicted a lower rate of 5-year survival in members of a cohort
analyzed by Hoshida et al. (2009) (Figure 4J). Next, we silenced
TCF7 in HCC cells and established stably silenced cell lines
(Figure 4K). Notably, TCF7 depletion suppressed Sox2 expres-
sion. We observed that TCF7 silencing dramatically impairedg in Liver CSCs
or shCtrl-treated HCC primary CSC cells.
C primary samples. Similar observations were obtained from three lncTCF7-
xamined. Results of Hep3B and Sample#1 are represented. Data are shown as
s and subjected to correlation analysis. Data were normalized to 18S rRNA
.
pletion. Representative sphere formation is shown on the left panel. Scale bar,
ght panel).
rn blot (upper panel) and quantitative real-time PCR (lower panel) analyses.
eri-tumor tissues were assigned a value of 1.
orescence staining. Scale bar, 10 mm.
bar, 100 mm.
nce with the 5-year followup protocol devised in Hoshida et al. (2009) (n = 80).
HCC cell lines and HCC primary cells. Data are shown as means ± SD.
ell frequency (N) as analyzed by a limiting dilution assay (http://bioinf.wehi.edu.
f at least three separate experiments. See also Figure S4.
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oncosphere formation, tumor initiating capacity, and xenograft
growth in HCC cell lines and primary cells (Figures 4L–4N, and
data not shown). In sum, lncTCF7 initiates TCF7 expression to
activate the Wnt signaling pathway, leading to priming of liver
CSC self-renewal and tumor propagation.
LncTCF7 Recruits the SWI/SNF Complex
LncRNAs are considered to exert their functions through RNA-
interacting proteins that regulate gene expression by various
mechanisms (Geisler and Coller, 2013). Therefore, we performed
an RNA pull-down assay with biotin-labeled lncTCF7 to search
for potential lncTCF7-associated proteins. BRG1, BAF170, and
SNF5, three core subunits of the SWI/SNF complex, were iden-
tified to bind lncTCF7 in liver CSCs (Figures 5A and 5B and Fig-
ures S5A–S5C). The interaction of lncTCF7 with the three SWI/
SNF components was further validated by RNA immunoprecip-
itation (RIP) (Figure 5C and Figure S5D). However, lncTCF7
depletion did not influence expression levels of BAF170,
BRG1, and SNF5 (Figure 5D), suggesting that lncTCF7 was not
involved in the post-translational regulation of the SWI/SNF
complex. Moreover, lncTCF7 colocalized with BAF170 in the
nuclei of HCC oncosphere cells, whereas lncTCF7 was poorly
expressed in the nuclei of non-sphere cells (Figure 5E). These
data indicate that lncTCF7 associates with the SWI/SNF com-
plex in the nuclei of liver CSCs.
We next constructed a series of lncTCF7 truncations tomap its
binding fragment with the SWI/SNF complex. We found that the
30-end fragment of lncTCF7 (nt 468 to 683) was sufficient to bind
BAF170, BRG1, and SNF5 (Figure 5F). A stable stem-loop struc-
ture of the 30-end fragment was predicted by RNA folding anal-
ysis (Figure S5E). The binding of the 30-end region of lncTCF7
with BAF170 was further confirmed by an RNA electrical mobility
shift assay (EMSA) (Figures 5G and 5H). Unlabeled lncTCF7
probes competitively disrupted this binding capacity. Addition-
ally, lncTCF7 showed high binding affinity (dissociation constant
[Kd] 36.24 nM) (Figure 5I). These data indicate that lncTCF7
directly binds to the SWI/SNF complex with high affinity.
LncTCF7 Triggers TCF7 Expression to Activate Wnt
Signaling
Given that the SWI/SNF complex regulates gene transcription by
binding to promoter loci and refolding chromatin (Roberts and
Orkin, 2004), we then detected whether lncTCF7 influenced
BAF170 occupancy of the promoter locus of the TCF7 gene.
We analyzed a 3 kb locus upstream from the transcription start
sites (TSSs) of the TCF7 gene. We found that lncTCF7 depletion
abrogated the binding capacity of BAF170with (approximately) a
1,160 to 1,048 bp segment of TCF7 promoter (Figure 6A),
suggesting that this segment was the binding site for lncTCF7.
Through luciferase reporter assays, we identified (approxi-
mately) a 1,200 to 1,100 bp segment of TCF7 promoter
as a sufficient binding site for BAF170 (Figures 6B–6D). Finally,
we observed via a DNase I digestion assay that lncTCF7 or
BAF170 knockdown significantly impaired the chromatin acces-
sibility of the TCF7 locus (Figure 4E). By contrast, BAF170 was
not recruited on the promoters of the stem pluripotent factors,
as assessed through chromatin immunoprecipitation (ChIP) an-
alyses (Figures S6A–S6D), suggesting that BAF170 had an indi-
rect effect on the expression of stem pluripotent factors. These420 Cell Stem Cell 16, 413–425, April 2, 2015 ª2015 Elsevier Inc.data suggest that lncTCF7 recruits the SWI/SNF complex to
the TCF7 promoter, thereby leading to its activation.
Notably, the SWI/SNF complex was highly expressed in HCC
tumors and liver CSCs (Figure 6F and data not shown), suggest-
ing that the SWI/SNF complex may be implicated in the regula-
tion of liver CSC self-renewal. Consequently, BAF170 depletion
dramatically reduced expression of TCF7 and Nanog (Fig-
ure 6G), as well as Wnt downstream targets such as Sox2,
CCND1, and CCND2. Additionally, BAF170 knockdown signifi-
cantly impaired the ability of oncosphere formation derived
from HCC cell lines and HCC primary cells (Figure 6H). Finally,
BAF170 knockdown also remarkably reduced tumor-initiating
capacity and xenograft tumor growth (Figures 6I–6K). Similar re-
sults were observed by depleting SNF5 and BRG1 (data not
shown). All together, our data show that lncTCF7 triggers
TCF7 expression through recruitment of the SWI/SNF complex,
leading to priming of the self-renewal of liver CSCs and tumor
initiation.
DISCUSSION
Recently, CSCs have been identified in many solid tumors,
including breast, lung, liver, brain, colon, prostate, and bladder
cancers (Haraguchi et al., 2010; O’Brien et al., 2007; Visvader
and Lindeman, 2012). CSCs have stem characteristics such as
self-renewal and differentiation. CSCs may account for cancer
relapse and metastasis due to their invasive and drug-resistant
capacities (Gupta et al., 2009). Several surface markers have
been identified in liver CSCs. However, details of liver CSC
biology remain largely unknown. In this study, we isolated the
CD13+CD133+ subpopulation of cells from HCC cell lines and
HCC primary cells and identified them as liver CSCs. Through
transcriptome microarray analysis, we identified 286 differen-
tially expressed noncoding RNAs in liver CSCs. Among these
highly expressed lncRNAs in liver CSCs, we defined an lncRNA
termed lncTCF7 that plays a critical role in priming the self-
renewal of liver CSCs.
LncRNAs have been reported to play widespread roles in gene
regulation and other cellular processes (Batista and Chang,
2013; Flynn and Chang, 2014). LncRNAs exert their functions
via diverse mechanisms, including cotranscriptional regulation,
modulation of gene expression, scaffolding of nuclear or cyto-
plasmic complexes, and pairing with other RNAs (Ulitsky and
Bartel, 2013). Notably, accumulating evidence shows that
lncRNAsmodulate gene expression as epigenetic modifiers (Ka-
neko et al., 2014; Klattenhoff et al., 2013; Prensner et al., 2013;
Tsai et al., 2010; Zhu et al., 2013). Here we found that lncTCF7
activates TCF7 expression in cis through recruitment of the
SWI/SNF complex. TCF7 expression triggers Wnt signaling to
initiate self-renewal of liver CSCs. Although lncTCF7 is ex-
pressed in the antisense direction, it fails to form an lncTCF7-
TCF7 mRNA complex for the regulation of TCF7 expression.
The Wnt signaling plays a pivotal role in self-renewal and differ-
entiation of CSCs (Hoffmeyer et al., 2012; Myant et al., 2013).
Aberrant activation of Wnt signaling is implicated in liver cancer
and other chronic liver diseases (Huch et al., 2013; Wang et al.,
2013a). Here we show that depletion of TCF7 and Wnt down-
stream target genes impairs the self-renewal of liver CSCs and
their tumor-initiating capacity, suggesting that TCF7-mediated
Figure 5. LncTCF7 Associates with the SWI/SNF Complex
(A) Biotin-RNA pull-downs were performed with nuclear extracts of oncosphere cells using full-length lncTCF7 transcript (sense), antisense, and other two
lncTCF7 intron controls. This was followed by mass spectrometry. Band a, BRG1; band b, BAF170; band c, SNF5.
(B) Three core components of the SWI/SNF complex were confirmed by immunoblotting. b-actin was used as a loading control.
(C) The interaction of lncTCF7 with BAF170, BRG1, and SNF5 was verified by an RNA immunoprecipitation (RIP) assay. Results are shown as means ± SD. **p <
0.01 by two-tailed Student’s t test.
(D) LncTCF7 depletion does not alter the protein levels of BAF170, BRG1, and SNF5.
(E) LncTCF7 was visualized by RNA-FISH, and immunofluorescence staining of BAF170 in Huh7 oncosphere and non-sphere cells was performed. Scale bar,
10 mm.
(F) Mapping analysis of SWI/SNF-complex-binding domains of lncTCF7. Shown are the following: schematic diagram of lncTCF7 full-length and truncated
fragments (top panel); in vitro transcribed biotin-labeled RNA (middle panel); andwestern blot of BAF170, BRG1, and SNF5 in RNApull-down samples by different
lncTCF7 fragments (bottom panel).
(G) BAF170 protein and biotin-labeled lncTCF7 (468-683 nt) probes were incubated for an EMSA assay.
(H) Different concentrations of BAF170 protein were incubated with lncTCF7 probes (5 nM) and followed by EMSA assays as above (G).
(I) Binding affinity of lncTCF7 with BAF170 as determined by five independent EMSA assays. Non-linear regression curves were generated by GraphPad Prism.
See also Figure S5.
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Figure 6. LncTCF7 Triggers TCF7 Expression to Activate Wnt Signaling
(A) An approximately 1,160–1,048 bp fragment of the TCF7 promoter is sufficient for the binding of BAF170 by ChIP-quantitative PCR analysis. Data are shown as
means ± SD.
(B) BAF170 was silenced in liver CSCs by two independent shRNAs.
(legend continued on next page)
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Wnt signaling is critical for sustaining liver CSC self-renewal and
tumorigenicity.
CSCs harbor the stem cell properties of self-renewal and dif-
ferentiation (Visvader and Lindeman, 2012). In this study, we
found that there was no significant difference in the proliferative
capacity between liver CSCs and non-CSCs, as assessed by
cell-cycle analysis and immunofluorescence staining. Actually,
CSCs exist mainly in the G1/G0 phase or G0 phase with dormant
or slow-growing properties (Haraguchi et al., 2010). As such, it
might be hard to distinguish the proliferation differences be-
tween liver CSCs and non-CSCs via Ki67 staining or DNA con-
tents assayed by propidium iodide (PI). Also, the self-renewal
properties of different cancer types may have different prolifera-
tion characteristics. The maintenance of self-renewal is an
extremely complicated biological process, which is controlled
by epigenetic states, pluoripotent transcription factors, epige-
netic complexes, and many developmental pathways (Bou-
mahdi et al., 2014; Ohnishi et al., 2014; Visvader and Lindeman,
2012). Our data support the idea that lncTCF7-mediated Wnt
signaling activation in hepatic CSCs plays a critical role in the
regulation of liver CSC self-renewal.
TCF7, as a T cell factor, is best known for its function in T
lymphocyte development and multipotential hematopoietic
cell self-renewal (Weber et al., 2011). TCF7 can initiate the
Wnt signaling cascade as an upstream trigger (Cui et al.,
2013; Weber et al., 2011). TCF7/ mice developed intestinal
and mammary adenomas, implying a role for TCF7 in tumor
suppression (Yu et al., 2012). In this study, we demonstrate
that TCF7 is required for the self-renewal of liver CSCs and tu-
mor propagation and acts as a tumor promoter. TCF7 is regu-
lated by lncTCF7 in liver CSCs to trigger the Wnt signaling
pathway, which primes the self-renewal of liver CSCs. A
recent study reported that TCF7 functions as a tumor enhancer
in tumorigenesis after ocular transplantation of embryonic
stem cell-derived retinal progenitor cells (Cui et al., 2013).
Consistently, our findings reveal that lncTCF7 mediated TCF7
expression, which initiates the Wnt signaling cascade to prime
self-renewal of liver CSCs and hepatic tumorigenicity as a
tumor promoter. CSCs are analogous to tissue-specific stem
cells in that they contribute to long-term growth and are
responsible for the maintenance and growth of tumors
(Beck and Blanpain, 2013). Transcriptional regulation is
one of the key regulatory mechanisms determining cell fate,(C and D) Different loci of TCF7 promoter were constructed into pGL3 vector an
shown as means ± SD.
(E) LncTCF7 or BAF170 depletion increases chromatin accessibility at the promo
(F) BAF170 and BRG1 were highly expressed in HCC tumor tissues (n = 30). Data
were assigned a value of 1.
(G) TCF7, pluripotent transcripts, and Wnt pathway targets were detected in BAF
blot (right panel) analyses. Quantitative PCR data are shown as means ± SD.
(H) BAF170 depletion impairs the capacity of oncosphere formation in cells derived
sphere-forming cells were calculated as means ± SD (right panel).
(I) BAF170-silenced or shCtrl HCC primary tumor cells or Huh7 cells were diluted
during 4 months. n = 6 for each group.
(J) BAF170-silenced or shCtrl HCC primary tumor cells and Huh7 cells were sub
Results are shown as means ± SD. n = 10 for each group.
(K) Tumorigenic cell frequency in BAF170-silenced and shCtrl primary tumor cells
elda/). #6, sample #6; CI, confidence interval.
*p < 0.05 and **p < 0.01 by two-tailed Student’s t test. Data represent at least thwhich includes cis-regulatory elements and transacting factors.
Among all transacting factors, chromatin remodeling regulation
plays a pivotal role in gene transcription (Krasteva et al.,
2012; Narlikar et al., 2013), which depends on ATP-dependent
chromatin remodeling complexes. The SWI/SNF complex is
composed of 12–15 subunits containing one of the two cata-
lytic ATPase subunits, SMARCA4/BRG1 or SMARCA2/BRM,
and several core components such as SMARCB1/SNF5,
BAF170, and BAF155 (Helming et al., 2014; Wilson and Rob-
erts, 2011). The SWI/SNF complex regulates gene expression
through mobilizing nucleosomes and remodeling chromatin
using the energy of ATP hydrolysis, suggesting its critical role
in gene expression. Inactivating mutations in several SWI/SNF
subunits cause various human cancers (Helming et al., 2014;
Jones et al., 2010; Kadoch et al., 2013), suggesting that
some components act as tumor suppressors. A recent study
reported that the long noncoding RNA SChLAP1 associates
with the SNF5 subunit to promote prostate cancer progress
by antagonizing the function of the SWI/SNF complex (Pre-
nsner et al., 2013), which implies that SNF5 functions as a tu-
mor suppressor. Here we found that lncTCF7 can recruit the
SWI/SNF complex to trigger TCF7 expression, leading to prim-
ing of liver CSC self-renewal. Additionally, we observed that
BAF170, BRG1, and SNF5 are highly expressed in HCC spec-
imens and liver CSCs, whose depletion impairs tumor-initiating
capacity and tumor propagation (Figure 6, and data not shown),
suggesting that these three components act as tumor pro-
moters. Therefore, how the SWI/SNF complex components
function in tumorigenesis remains to be further investigated.
In conclusion, lncTCF7 can promote liver CSC self-renewal
and tumor propagation through activation of Wnt signaling by re-
cruiting the SWI/SNF complex to the TCF7 promoter. Our find-




Total RNA, extracted as described (Wang et al., 2013b) from human CSC
oncospheres and control cells, was subjected to northern blot assays. An
lncTCF7-specific DNA sequence (nt320–683) was cloned into pcDNA4/myc-
his B Vector. Radioactive RNA probe with a length of 363 nt was generated us-
ing [a-32P] CTP (Perkin Elmer) and the Riboprobe in vitro transcription labeling
system (Promega).d subjected to luciferase reporter assays in BAF170-silenced cells. Data are
ter of TCF7 by DNase I digestion assays. Data are shown as means ± SD.
were normalized to endogenous 18S rRNA expression and peri-tumor tissues
170-silenced HCC cells by quantitative real-time PCR (left panel) and western
fromHCC cell lines and HCC primary cells. Scale bar, 100 mm. Percentages of
and subcutaneously implanted into BALB/c nude mice. Tumors were observed
cutaneously injected into BALB/c nude mice for observation of tumor growth.
was analyzed with a limiting dilution assay (http://bioinf.wehi.edu.au/software/
ree independent experiments. See also Figure S6.
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RNA-FISH
Fluorescence-conjugated lncTCF7 probes were used for RNA-FISH.
RNA-FISH was performed as previously described (Wang et al., 2014).
Hybridization was carried out using DNA probe sets (Biosearch Technolo-
gies) according to the protocol of Biosearch Technologies. Oncosphere
and control cells were observed with a FV1000 confocal laser microscope
(Olympus).
RNA Pull-down and Mass Spectrometry Assay
RNA pull-down was performed as described (Klattenhoff et al., 2013). In vitro
biotin-labeled RNAs (lncTCF7, its antisense RNA, and two control RNAs from
two introns of lncTCF7) were transcribed with the biotin RNA labeling mix
(Roche) and T7 RNA polymerase (Roche) treated with RNase-free DNase I
(Promega) and purified with RNeasy Mini Kit (QIAGEN). Biotinylated RNA
was incubated with HCC oncosphere cell nuclear extracts, and pull-down
proteins were run on SDS-PAGE gels as described (Xia et al., 2013). Mass
spectrometry followed.
RNA-EMSA Assay
EMSA experiments were performed using a LightShift Chemiluminescent
RNA EMSA Kit (Thermo Scientific). The shifted signals were quantified and
plotted against the amount of BAF170 protein with GraphPad Prism 6
(GraphPad).
Statistical Analysis
Data were analyzed with a double-sided Student’s t test using the SPSS 13.0
software and GraphPad Prism 6. Tumorigenic cell frequency was calculated
based on extreme limiting dilution analysis (ELDA) (http://bioinf.wehi.edu.au/
software/elda/). p < 0.05 was considered statistically significant. For other
methods see the Supplemental Information.
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